

FINAL
Press Release

**Alfasigma Streamlines Manufacturing Footprint to Sharpen Strategic Focus
and Accelerate Innovation and Growth**

Bologna, 17 April 2026 – Alfasigma, a global pharmaceutical company headquartered in Italy, today announced that it has entered into an agreement for the sale of 100% of the share capital of its subsidiary Sofar S.p.A. (“Sofar”), which includes the production site in Trezzano Rosa, to Fine Foods & Pharmaceuticals N.T.M. S.p.A. (“Fine Foods”).

The transaction reflects Alfasigma's strategy to focus its investments where it can be truly distinctive, maximising impact for patients, and building sustainable competitive advantage for future growth.

Fine Foods is an independent Italian CSDMO (Contract Solutions Development and Manufacturing Organization) headquartered in Bergamo, listed on Euronext STAR Milan (ticker: FF), and active in contract development and manufacturing for the nutraceutical, pharmaceutical, and cosmetics sectors.

Alfasigma will retain ownership of the products currently manufactured at the Trezzano Rosa manufacturing site. Production and supply will continue through a long-term contract manufacturing agreement with Fine Foods, ensuring continuity of supply for patients, consumers and customers.

CEO Francesco Balestrieri stated: *“As Alfasigma continues to grow at pace, we are making deliberate strategic choices to remain focused on what matters most. By streamlining elements of our manufacturing footprint, we are strengthening our capacity to invest selectively in areas where we can be distinctive and make the greatest impact. This focus allows us to accelerate innovation and support our core therapeutic priorities in immunology, gastroenterology and vascular disease. Italy remains a cornerstone of Alfasigma's industrial and strategic presence, with majority of products manufactured in Italy. We recently approved an investment plan of approximately €130 million over the next three years, largely focused on Italy, to strengthen capabilities in centres of excellence that are critical to our future portfolio.”*

This includes continued and significant investment in the Alanno manufacturing site, Alfasigma's centre of excellence for sterile manufacturing, and in the Pomezia manufacturing site, where the site's softgel technology is state-of-the-art, supporting advanced, flexible manufacturing aligned with future needs. Also, in the Sermoneta Biosint manufacturing site, where focus will be mainly around modernizing drug substance production processes.

Alfasigma is recognised among Italy's leading pharmaceutical companies.

The completion of the transaction remains subject to the satisfaction of customary conditions precedent for transactions of this nature.

About Alfasigma

Alfasigma is a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered today in Bologna and Milan. The Group's products are distributed in more than 100 markets worldwide. Alfasigma operates offices across major European countries, as well as in the United States, China, and Mexico; production facilities in Italy, Spain, and the United States; and R&D laboratories located in Italy. The company employs approximately 4,000 professionals dedicated to the research, development, production, and distribution of medicinal products. Its portfolio ranges from consumer healthcare products and primary care treatments to specialty and rare disease medications, with key therapeutic areas including gastroenterology, vascular health, and immunology.

For further information, contact:

Alice Beretta

alice.beretta@omc.com

Giulia Bergami

pressoffice@alfasigma.com